Answers are grounded in this paper and cite their sources.
Prospective study shows HLADQA1*05G>A screening improves clinical outcomes in IBD patients, suggesting better therapy decisions.
Background The HLADQA1*05G>A genetic variation is a clinically-useful screening tool for identifying tumor necrosis factor-α antagonists (TNFA)anti-drug antibody (ADA) risk as well as TNFA loss of response and discontinuation. Aims We hypothesize that an additional use for HLADQA1*05G>A screening is guiding the selection of TNFA vs non-TNFA-based advanced inflammatory bowel disease (IBD) treatments. Methods A prospective cohort study was conducted in IBD patients being considered for advanced therapy. Participants were assessed in one of 2 cohorts: 1) those where advanced therapy selection was based on physician preference (controls); 2) those where HLADQA1*05G>A screening was used to select the use of TNFA vs non-TNFA advanced therapy (screened cohort). Specifically, TNFA therapy was selected for wildtype genotypes and non-TNFA therapy was selected for variant genotypes. Participants were assessed for clinical remission at 1-year, treatment discontinuation, adverse drug events, ADA formation, and other important clinical outcomes. Post-hoc analyses examined the effect of screening on individual genotype groups. Results A total of 233 participants seen at a tertiary care centre in London, ON were included in the final analyses (screened cohort, n = 75; control cohort, n = 158). The distribution of genotypes in the screened cohort was 48 GG, 20 GA, 7 AA. TNFA therapy was the most used advanced therapy in both groups (screened, N = 48/75, 64.0%; controls, N = 84/158, 53.2%). Screened participants were more likely to achieve clinical remission at 1-year vs controls (N = 61/75, 81.3% vs 102/158, 64.6%, p = 0.0093), less likely to be co-prescribed combination therapy (N = 4/75, 5.3% vs 71/158, 44.9%, p < 0.0001), report fewer adverse drug events (ADE) (N = 13/75, 17.3% vs N = 56/158, 35.4%, p = 0.0055) and had a lower frequency of ADA formation (N = 0/75, 0.0% vs N = 11/158, 7.0%, p = 0.018). Similar frequencies of drug discontinuation, hospitalizations, surgery, dose escalation and rescue glucocorticoid use (RGU) were seen in both groups. Post-hoc analyses highlighted that HLADQA1*05G>A variant carriers identified by screening derived the most clinical benefit. Screened variant carriers had the most clinical remission (92.6%) with the fewest ADEs (3.7%), fewest drug dose escalations (11.1%) and requiring less RGU (7.4%) compared to unscreened variant carriers and individuals with a wildtype genotype, with or without screening. Conclusions HLADQA1*05G>A-screening was associated with disease remission, fewer adverse events and a lower incidence of ADA formation when used to select TNFA vs non-TNFA therapy. Variant carriers derive the most benefit from screening. We confirm an additional role for HLADQA1*05 screening is guiding TNFA vs non-TNFA IBD drug selection.
No takes yet. Share an insight, caveat, or question.
Bueno et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: